EMA — authorised 2 December 2022
- Marketing authorisation holder: AMRYT PHARMACEUTICALS DAC
- Status: approved
🇪🇺 Sandostatin in European Union
EMA authorised Sandostatin on 2 December 2022
Marketing authorisation
Sandostatin in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in European Union
Frequently asked questions
Is Sandostatin approved in European Union?
Yes. EMA authorised it on 2 December 2022.
Who is the marketing authorisation holder for Sandostatin in European Union?
AMRYT PHARMACEUTICALS DAC holds the EU marketing authorisation.